Fed. Cir.

Astellas Pharma, Inc. v. Lupin Ltd., No. 24-1766 (Fed. Cir. June 5, 2024)

General / Procedural

Court: U.S. Court of Appeals for the Federal Circuit
Case No.: No. 24-1766
Decided: June 5, 2024
Judge: See opinion
Document: Nonprecedential Opinion
Length: 2 pages

Full Text Analysis Cite this Opinion

Download Opinion (PDF)

NOTE: This order is nonprecedential. United States Court of Appeals

for the Federal Circuit ASTELLAS PHARMA, INC., ASTELLAS

IRELAND CO., LTD., ASTELLAS PHARMA

GLOBAL DEVELOPMENT, INC.,

Plaintiffs-Appellants

LUPIN LTD., LUPIN PHARMACEUTICALS, INC.,

ZYDUS PHARMACEUTICALS (USA) INC.,

ZYDUS LIFESCIENCES LTD.,

Defendants-Appellees

2024-1766

Appeal from the United States District Court for the District of Delaware in No. 1:23-cv-00819-JFB-CJB, Senior Judge Joseph F. Bataillon.

O R D E R

The parties having so agreed, it is ordered that: (1) The proceeding is DISMISSED under Fed. R. App.

P. 42 (b).

22 ASTELLAS PHARMA, INC. V. LUPIN LTD.

(2) Each side shall bear their own costs.

FOR THE COURT

June 5, 2024

Date

ISSUED AS A MANDATE: June 5, 2024

Text extracted from the official PDF and reflowed for reading. It is not a certified transcript — the PDF linked above is the authoritative document.

Analysis is coming soon.

A plain-English account of the issues, facts and holding, written by Patent Case Watch. The opinion itself — its full text, its PDF and everything else on this page — stays free to read for everyone, always.

Cite this opinion

Astellas Pharma, Inc. v. Lupin Ltd., No. 24-1766 (Fed. Cir. June 5, 2024).

Record ID: CAFC-24-1766-20240605
Permalink: https://patentcasewatch.com/opinions/CAFC-24-1766-20240605

No reporter citation is shown because the official source does not supply one; none is inferred here. Check the opinion and a citator before relying on this form.

Source: Federal Circuit opinions and orders · retrieved August 15, 2026 · Report an error